Reversibly targeting noncatalytic cysteine residues could lead to covalent drug molecules with improved potency and selectivity but with less potential for off-target adducts, Jack Taunton of the ...
For a class of drugs once treated with trepidation, things are looking up for covalent irreversible kinase inhibitors, which are basking in the glow of US Food and Drug Administration (FDA) approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results